Aslan Fred
Known title: Chief Executive OfficerCIK: 0001909362
Associated companies
Transaction History
| ARTV | ▼ Sell | Open Market | 23,463 | $169K | 10/6/2026 | View on chart |
| ARTV | ▼ Sell | Open Market | 61,696 | $422K | 10/5/2026 | View on chart |
| ARTV | ▲ Buy | Grant | 110,000 | $0 | 9/15/2026 | View on chart |
| ARTV | ▲ Buy | Grant | 45,000 | $0 | 9/10/2026 | View on chart |
| ARTV | ▼ Sell | Open Market | 23,429 | $256K | 9/8/2026 | View on chart |
| ARTV | ▼ Sell | Open Market | 61,888 | $690K | 9/3/2026 | View on chart |
| ARTV | ▼ Sell | Open Market | 27,116 | $244K | 5/19/2026 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 14,600 | $58K | 2/15/2026 | View on chart |
| ARTV | ▲ Buy | Grant | 366,850 | $0 | 2/15/2026 | View on chart |
| ARTV | ▼ Sell | Open Market | 3,187 | $19K | 12/15/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 869,136 | $0 | 12/12/2025 | View on chart |
| ARTV | ▼ Sell | Open Market | 6,375 | $22K | 11/17/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 6,347 | $21K | 11/15/2025 | View on chart |
| ARTV | ▼ Sell | Open Market | 25,500 | $153K | 10/17/2025 | View on chart |
| ARTV | ▼ Sell | Open Market | 25,500 | $70K | 8/15/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 4,472 | $12K | 8/15/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 4,472 | $10K | 5/15/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 200,000 | $0 | 3/5/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 228,905 | $0 | 7/22/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium
Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium. Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.